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Abstract
Rehabilitation professionals work with a variety of people with various disabilities 
and disease states.  Oftentimes, those disease states are treated with medications.  An 
understanding of the most common types of medications that can cause ototoxicity, such as 
aminoglycides, cisplatin and loop diuretics can assist in the vocational rehabilitation process. 
Rehabilitation professionals are encouraged to establish positive communication with the 
consumers in order to foster a relationship of trust.  Furthermore they are encouraged 
to establish relationships with pharmacists for an understanding of the implications of 
commonly used medications on hearing. 
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Introduction
Both general and specialized rehabilitation professionals need to have 
an understanding of the effects of mediations on their consumers..  State, 
federal and private rehabilitation professionals can work with homogeneous 
or heterogeneous populations with regards to the type of disability reported 
in each population.  For example, some homogeneous caseloads may focus 
on people with hearing loss, spinal cord injuries, traumatic brain injuries, or 
learning disabilities, to name a few.  These are specialized caseloads in which, 
ideally, the rehabilitation professional is an expert.  This is often the case 
with people who are blind, as is evident from several states having separate 
rehabilitation agencies to address the specialized needs of this population. 
Another common caseload focus is serving people who have hearing loss. 
Some states have a designated agency to serve the individualized needs 
of this population while others specify certain caseloads to best serve this 
population.  However, the ability to set aside an entire agency, or even a 
caseload, is often not feasible, especially in sparsely populated states 
(Watson, Jennings, Tomlinson, Boone & Anderson, 2008).  Sometimes, in 
rural areas, the distance the consumer and/or the rehabilitation professional 
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need to travel for basic services is excessive; therefore, it is not feasible to 
have a specialized counselor.  In light of not all consumers being served by 
specialty counselors who focus on their type of disability, being served by a 
general rehabilitation professional is the likely scenario for the majority of 
consumers.  
Ototoxic Medications
This paper focuses on commonly used medications that may cause 
ototoxicity and the implication for rehabilitation professionals serving the 
people who experience this side effect. Ototoxicity is a serious adverse drug 
reaction, and may result in cochleotoxocity, or permanent irreversible bilateral 
sensorineural hearing loss.  It can also cause ataxia, nausea, and vertigo 
(vestibulotoxicity; Xie, Talaska, & Schact, 2011).  These possible reactions 
warrant attention.  The consumer may or may not start the caseload with 
severe irreversible hearing loss, but it is possible for this to occur because 
of the types of medications consumers are prescribed for the various other 
health conditions they may have. 
Aminoglycosides
Aminoglycosides (AGs) are a class of antibiotics (e.g., gentamicin, 
tobramycin, amikacin, neomycin, streptomycin) commonly used to treat 
infections.  Ototoxic effects vary within this class.  The ranking of AGs from 
most toxic to least toxic to the auditory system are as follows: neomycin, 
tobramycin, kanamycin, gentamicin and amikacin (Rybak, 2007). 
 
When properly administered, AGs rapidly enter the inner ear (Fisman & 
Kaye, 2000).  However, AG concentration levels do not appear to correlate 
well with incidence of ototoxicity. Prolonged use of AGs over five to six 
months has shown evidence of AGs in sensory cells (Barza, Ioannidis, 
Cappelleri, & Lau, 1996; Dulon, Aran, Zajic, & Schacht, 1986).  This 
prolonged use may be the cause of damage to type 1 sensory hair cells in 
the vestibular organ and the outer hair cells in the origin of Corti (Rybak, 
2007).  Damage begins gradually from the base of the cells that detect high 
frequency sounds and progresses to the apex of the cochlea, which detects 
low frequency sound (Huizing & deGroot, 1987).  Conversely, Hinojosa 
and Lerner (1987) discovered cochlear ganglion cell destruction without 
damage to the hair cells.
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In addition to taking the medication, there are other factors that can 
increase the ototoxic effects of the AGs.  Noise induction (Zimmerman & 
Lahav, 2012), concurrent use of other ototoxic medications (Ding & Salvi, 
2010; Garcia, Martinez, Agustí, Mencía & Asenjo, 2001), mutations in an 
individual’s sequences of mitochondrial ribosomal RNA (Fishel-Ghodsian, 
et al., 1997; Xing, Chen, & Cao, 2007) and other biomedical reasons (Guan, 
Fischel-Ghodsian, & Giuseppe, 2000) may exacerbate the ototoxic effects 
of the AGs. 
Cisplatin
Cisplatin is an antineoplastic agent used to treat cancers such as ovarian, 
testicular, and bladder cancer.  This drug has been found to be ototoxic 
to the point of causing irreversible hearing loss in the cochlea (Schacht, 
Talaska, & Rybak, 2012).  Similar to AGs, cisplatin affects the hair cells in 
the cochlea from the base to the apex. In other words, the ability to hear 
high frequencies will be affected first, and then the continuum of loss will 
progress to the lower frequencies (Church, Blakley, Burgio, & Gupta, 2004; 
Estivill, et al., 1998; Harris, Gilbert, Lormore, Musunuru, & Fritsch, 2011; 
Hinojosa, Riggs, Strauss, & Matz, 1995).  Other factors, such as the dose 
administered, combined with noise exposure may also contribute to a higher 
risk of cisplatin-induced ototoxicity (Bokemeyer et al., 1998; Li, Womer, & 
Silber, 2004).   
Loop Diuretics
Edema, defined as swelling, and occurs as a result of excess fluid trapped 
in the interstitium. It is often caused by disease states such as heart failure, 
renal insufficiency, or liver cirrhosis.  Edema is most commonly treated 
with loop diuretics that include furosemide, bumetanide, and ethacrynic 
acid.  Furosemide, administered orally or intravenously, is most commonly 
associated with ototoxicity (Chiodo & Alberti, 1994).  This is caused by the 
blockage of fluid movement out of the stria vasularis affecting the marginal 
cells.  However, unlike AGs and cisplatin, loop diuretics have very little effect 
on the hair cells (Ikeda, Oshima, Hidaka, & Takasaka, 1997).  The hearing 
loss is usually temporary and correlates with the amount received; the higher 
the amount of furosemide given, the greater the hearing loss (Chiodo & 
Alberti, 1994).  Additionally, when the loop diuretic is discontinued, the 
hearing may be restored. 
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Implications for Rehabilitation Professionals
Rehabilitation professionals whose primary responsibility is assisting 
consumers in obtaining and maintain employment need to have an 
understanding of the types of medications the consumers may take.  The 
consumers may have issues in regards to adjusting to new hearing loss. For 
example, they may not know the types of technology available to them 
or how to use these technologies. Furthermore, in the event they are to 
interview, not knowing how to use technology or simple communication 
strategies may have negative effects in terms of employment outcomes. As 
rehabilitation professionals work on such cases, they are encouraged to be 
cognizant of changes in the consumers’ health, and be knowledgeable of the 
medications the consumers are prescribed.  Developing a positive supportive 
working relationship with the consumer is vital to the exchange of this type 
of information. Furthermore, it behooves the rehabilitation professional 
to establish a relationship with a pharmacist.  This healthcare professional 
is better able to explain the effects of the consumer’s medications. The 
rehabilitation professional can use this information, in conjunction with 
information from a comprehensive assessment, to develop a plan of services. 
Establishing this relationship may take a bit of effort, and one must be 
cautious not to share confidential information. There are several ways to do 
this, and each situation will be different; the salient factor is communication. 
The rehabilitation professional may simply make an appointment with an 
area pharmacist and discuss ototoxicity. Pharmacists may also be invited 
to speak at the rehabilitation professional’s monthly quarterly or annual 
meetings or at local professional meetings.
If a more self-directed search is needed, several websites list the various 
medications that can cause hearing loss. A search of “organizations with 
ototoxic medication list 2014” resulted in about 275,000 results, with the first 
result being from the Northern Virginia Resource Center for Deaf and Hard 
of Hearing People (http://www.nvrc.org/hearing-loss-deafness/ototoxic-
drugs/). Another reliable source is from the World Health Organization 
(WHO: http://www.who.int/mediacentre/factsheets/fs300/en/). 
Conclusion
In addition to understanding the medications, rehabilitation professionals 
need to understand the potential ototoxic effects some medications can cause. 
As previously mentioned, a noisy environment (Zimmerman & Lahav, 
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2013) and other genetic issues (Fishel-Ghodsian, et al., 1997; Xing, Chen, 
& Cao, 2007) may compound hearing loss in consumers.  An understanding 
of hearing loss types, whether permanent or temporary, and the severity of 
the loss, is important for working with consumers. 
In addition to counseling, other psychological services may be necessary 
for those who expect a slow recovery or permanent loss.  Consumers may need 
to learn coping strategies for communication in their usual environments, 
which could have service implications.  The consumers may need training 
and counseling on the roles and functions of additional assistive technology, 
learn visual forms of communication, or even be trained for another career.
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